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OBJECTIVE: Certain drug classes alleviate the symptoms of Willis-Ekbom’s disease, whereas others aggravate
them. The pharmacological profiles of these drugs suggest that drugs that alleviate Willis-Ekbom’s disease
inhibit thyroid hormone activity, whereas drugs that aggravate Willis-Ekbom’s disease increase thyroid
hormone activity. These different effects may be secondary to the opposing actions that drugs have on the
CYP4503A4 enzyme isoform. Drugs that worsen the symptoms of the Willis-Ekbom’s disease inhibit the
CYP4503A4 isoform, and drugs that ameliorate the symptoms induce CYP4503A4. The aim of this study is to
determine whether Saint John’s wort, as an inducer of the CYP4503A4 isoform, diminishes the severity of Willis-
Ekbom’s disease symptoms by increasing the metabolism of thyroid hormone in treated patients.
METHODS: In an open-label pilot trial, we treated 21 Willis-Ekbom’s disease patients with a concentrated
extract of Saint John’s wort at a daily dose of 300 mg over the course of three months.
RESULTS: Saint John’s wort reduced the severity of Willis-Ekbom’s disease symptoms in 17 of the 21 patients.
CONCLUSION: Results of this trial suggest that Saint John’s wort may benefit some Willis-Ekbom’s disease
patients. However, as this trial was not placebo-controlled, the extent to which Saint John’s wort is effective as
a Willis-Ekbom’s disease treatment will depend on future, blinded placebo-controlled studies.
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& INTRODUCTION
Willis-Ekbom’s disease (WED), formerly known as rest-
less legs syndrome, is a common disorder (1-3). In Brazil,
the lifetime prevalence of WED is 6.40% (4). Recently (2010),
it has been suggested that the WED pathophysiology is
caused by an imbalance between the activities of thyroid
hormone (TH) and the dopaminergic system (IMBTH/DA
(5). This concept is based on the following findings: 1)
dopamine (DA) agonists reduce TH levels and alleviate
WED symptoms; 2) cytochrome P450 metabolizes TH, and
its inhibition (mainly of the CYP3A4 enzyme isoform)
aggravates WED symptoms; 3) induction of CYP3A4
alleviates WED symptoms; and 4) DA increases the
expression of cytochrome P450, which results in an increase
of TH metabolism (6-11). Furthermore, DA also modulates
TH by reducing the synthesis of thyroid stimulation
hormone (TSH) in the hypothalamus (12).
The major pathway of TH metabolism is through
sequential deiodination, but TH is also conjugated with
glucuronides and sulfates. Glucuronides are then excreted
into bile to act as intermediates in the enterohepatic cycle
and fecal excretion of thyroid hormone. Sulfation accelerates
the deiodination of different iodothyronines by type I
deiodinase and thus initiates the irreversible degradation
of the hormone (7). This second pathway is less prevalent
and represents approximately 20% of the total TH metabo-
lism (8). TH behaves similarly to a steroid hormone, and
most steroid hormones are substrates for the CYP3A4
enzyme isoform. There is strong evidence that when the
CYP3A4 isoform is induced, TH glucuronidation and
sulfation are also induced (8,9,13,14). Notably, many drugs
that relieve or worsen WED symptoms are inducers or
inhibitors, respectively, of the CYP3A4 isoform (Table 1).
Pramipexole is an effective treatment for WED that is a
typical DA agonist with selective affinity for the D2 receptor
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subfamily (15,16). Pramipexole regulates the expression of
many CYP450 enzymes through the tuberoinfundibular and
mesolimbic dopaminergic pathways (10,11); furthermore,
pramipexole administration decreases the release of TSH
(12). These two pharmacological actions of pramipexole
may be why it is effective as a WED treatmen. Xenobiotic
drugs may also aggravate WED symptoms through de-
creased dopaminergic signaling (17) (Table 1).
We believe that the non-genomic actions of TH, when
unmodulated, underlie WED pathophysiology. TH acts on
the mitochondria (18-20), which are responsible for adeno-
sine triphosphate (ATP) production, and it is known that
TH increases the number and activity of mitochondria (18).
TH has a remarkable range of action in the nervous system,
and it is essential for sensory systems (18,21). By increasing
the production of ATP, TH increases synaptic transmission
by enhancing purinergic neurotransmission (21,22). ATP,
which is also a neurotransmitter, is now recognized as
having a role in a wide range of nervous system activities,
including pain and mechanosensory transduction (22). ATP
acts as an excitatory neurotransmitter and is also present in
neurons of the dorsal root ganglia (22,23). These neurons
have an axon that is connected to peripheral somatosensory
receptors (PSS) (23). By enhancing ATP production, TH
enhances PSS receptor signaling to the somatosensory
cortex; therefore, if modulation does not occur, WED
symptoms may ensue. In the so called ‘‘forbidden zone for
sleep,’’ the lowest propensity for sleep occurs in the few
hours before sleep onset (during the human circadian
rhythm) (24,25), concomitantly with a steep increase in the
activity (thyrotropin-evening-surge) of the TH axis (26) and
an increase in the daily severity of WED symptoms (2,3).
Many medications relieve WED symptoms (17,27), and
most of them are able to correct IMBTH/DA directly by
inhibiting the TH axis (via CYP450) or indirectly by
enhancing dopaminergic signaling (5,17). DA agonists also
increase the activity of the diencephalon-spinal DA system,
which arises from the dorsal posterior hypothalamic
dopaminergic A11 cell group. This system sends projections
to the dorsal horn at all spinal levels and to the
preganglionic sympathetic neurons (28). There is evidence
that this system modulates pain inputs; when dysfunctional,
it also may contribute to WED symptoms (28,29).
In somatosensory physiology, PSS receptors in the legs
receive information from the environment and convey
signals to the somatosensory cortex via the dorsal root
ganglia (23), and when this signaling is not appropriately
modulated, WED symptoms may ensue. Phantom WED in
patients with leg amputation and in WED patients
secondary to total knee arthroplasty are examples of the
importance of low-threshold sensitivity to stimulation of the
peripheral sensory receptors (30-32). On their way to the
cortex, the sensory axons synapse in various relay nuclei, in
which electrochemical signals are regulated by a number of
interspersed neurons (18,23). The primary neural modula-
tion systems are the dopaminergic, GABAergic, glycinergic,
and opioidergic systems (18,23). The GABAergic system is
the predominant inhibitory system in the CNS (18), and if a
drug has the ability to enhance GABA signaling, it may
alleviate the WED symptoms. Drugs with this profile
include benzodiazepines, benzodiazepine-like drugs, and
carbamazepine. Drugs that inhibit the excitability of the
sensory neurons that convey messages to the cortex include
many anticonvulsant drugs, such as gabapentin, which is an
analogue of GABA (27). Clonidine, which is an alpha-2
adrenergic receptor agonist, is a sympatholytic agent that
relieves WED symptoms in many patients (27). The
beneficial effects of clonidine on RLS symptoms highlight
the importance of the connection between the sympathetic
system (SS) and the TH axis. The SS has nerve projections to
the thyroid gland and induces TH release (33) that, when
excessive, may cause IMBTH/DA. Clonidine targets the
enhanced functioning of the SS, which makes it a useful
drug for alleviating WED symptoms that are occasionally
generated in response to an exacerbation of the SS tonus. In
iron-deficient patients, WED is more common or symptoms
Table 1 - Suggested mechanisms by which some drugs aggravate WED. The drugs listed in Table 1 (substrates and/or
inhibitors of CYP3A4) affect WED by interfering with CYP3A4, thereby decreasing TH metabolism. In addition, some
drugs may cause a direct decline in dopaminergic signaling.
Drug classes Examples CYP3A4 substrates CYP3A4 inhibitors Effects on DA system
Calcium channel blockers Verapamil Yes +++ Yes ++ No
Diltiazem Yes +++ Yes ++
Selective serotonin reuptake inhibitors Fluoxetine Yes + Yes +
Paroxetine No Yes + No
Sertraline Yes + Yes ++
Citalopram Yes +++ No
Escitalopram Yes +++ No
Fluvoxamine No Yes +
Neuroleptics Haloperidol Yes +++ Yes ++ Yes: block DA
Chlorpromazine Yes + No D2 receptors
Clozapine Yes + Yes +
Pimozide Yes +++ Yes +
Quetiapine Yes +++ No
Anti-nausea agents Metoclopramide No No Yes: block DA D2
receptors
Lipid lowering agents Atorvastatin Yes +++ Yes +
Lovastatin Yes +++ Yes + No
Simvastatin Yes +++ No
Non-steroidal anti-inflammatory drugs Diclofenac Yes + Yes ++ No
Stimulants Caffeine Yes + Yes ++ No
(+ = mild, ++ = moderate, and +++ = strong), References: 9, 13, 14, and 17.
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are more severe, and WED patients who receive iron
treatment (34,35) often obtain symptom relief. These
findings strongly suggest that iron is central to WED
pathophysiology. We believe that the role of iron in WED
pathophysiology may also be explained by the notion that
IMBTH/DA is the main cause of WED.
Iron is a component of many enzymatic systems (18);
therefore, it is reasonable to assume that when it is lacking,
these enzymes will experience reduced activity levels in
accordance with the severity of the iron deficienc. In the
chain of reactions that lead to the synthesis of DA, iron is
part of the enzyme tyrosine hydroxylase that catalyzes the
conversion of tyrosine into L-DOPA. This step in the
synthesis of DA is rate-limiting (36); as such, it is possible
to infer that iron deficiency may result in decreased
production of DA. Additionally, iron is an integral part of
all cytochromes (18), including CYP450, which plays a
critical role in the degradation of TH. As such, it is
reasonable to assume that a lack of iron will upset the
balance between TH and DA in two ways: by decreasing
DA synthesis and diminishing TH metabolism.
& MATERIALS AND METHODS
Saint John’s wort trial
Saint John’s wort (SJW) is a standardized extract of
hypericum perforatum L that is used to treat mild to moderate
depression in adults and children older than six years of
age. The usual adult dosage is 300 mg three times daily.
SJW is considered to be a fairly safe drug and is devoid of
serious side effects (37). SJW is an inducer of the CYP3A4
isoform (13,14) and is also believed to be a mild reuptake
inhibitor of the monoamines dopamine, norepinephrine,
and serotonin (37). Of the many compounds present in the
concentrated extracts of SJW, it is believed that hyperforin is
responsible for the induction of the CYP3A4 isoform (37).
Compounds present in the hypericum perforatum bush vary
according to different circumstances, such as the age of the
herb, season of the year, and the different proportions of
stalk, leaves, and flowers that are used to prepare the SJW
extract (37). SJW acts as a ligand for the nuclear pregnane X
receptor to enhance the expression of CYP4503A4 and also
stimulates the expression of P-glycoprotein (Pgp) (38),
which may result in decreased uptake of many xenobiotics
and compounds, including TH. It is known that CYP3A4
and Pgp are coexpressed in many tissues, mainly in the liver
and intestinal wall (8).
WED patients (n = 21, 16 female) were told the objective of
the trial, and they agreed to volunteer and signed a formal
consent for this study, which was approved by the board of
ethics on experimentation at our institution, the Faculdade
de Medicina de Jundiaı´ (protocol number 227-2012). All of
the studied patients were descendants of Italian and/or
Portuguese families. The following inclusion criteria were
applied: primary WED sufferers meeting all four criteria for
WED according to the IRLSSG (39); experiencing WED
symptoms at least three times a week; and having an
IRLSSG severity score (39) of at least 15. Additionally, the
patients should not have any clinical or therapeutic
conditions that may conflict with the experimental drug,
such as the use of drugs that are metabolized by
CYP4503A4. Exceptions to this latter criterion were three
patients who received TH replacement treatment and three
patients who were being treated with a low-dosage
antidepressant. Thirteen patients were drug-naı¨ve. Eight
patients had been taking pramipexole before the trial but
had stopped taking the medication for various reasons,
although their typical WED paresthesias had been almost
entirely alleviated by the use of pramipexole. All of the non-
drug-naı¨ve patients stopped taking pramipexole at least
three weeks before the SJW trial, and their WED symptoms
had returned.
The concentrated extract of SJW used in this trial, which
was purchased from Herbarium Laborato´rios (Curitiba,
Parana´), is marketed in Brazil under the brand name
Hipericin (300 mg of SJW dry extract in each capsule). This
experiment used only one SJW extract provider; therefore, it
was possible to establish that all of the patients would
receive equal amounts of the drug. SJW was tested at a daily
dose of 300 mg administered two or three hours before
bedtime for ten days, during which time the patients
received at least three telephone calls to verify treatment
compliance. The patients were rated pre- and post-treat-
ment using the IRLSSG severity rating scale (40), which was
translated and validated in the Brazilian Portuguese
language (41). After ten days of drug administration, the
patients were asked about the benefits of the treatment and
asked to report, in a face-to-face interview, their subjective
impression of the benefit as a percentage of relief in a
continuous scale from 0% (no improvement) to 100%
(complete improvement). To appraise the study results,
SJW was considered effective only if the patient expressed at
least 70% relief of their WED symptoms. It was also
necessary that the patients subjectively reported an
increased quality of sleep during the treatment compared
to before the treatment. From the eleventh day onward,
patients who were successful in the initial ten-day SJW trial
were prescribed the drug at a dosage of 300 mg for three
additional months, not on a daily basis but according to
their need to achieve relief from their WED symptoms. The
patients took the medication for four to five days and then
stopped taking it for as long as it would take for the WED
symptoms to recur. During the second phase of the trial, the
patients received at least one telephone call each week to
ascertain their adherence to the treatment. At the comple-
tion of the second phase of the trial, the patients were
questioned again in a face-to-face or telephone interview
regarding their impressions of the ongoing treatment and
were also asked if they would be willing to continue with
SJW as a treatment for their WED. At the end of the second
phase of the trial, all of the patients fulfilled out the IRLSSG
rating scale, and the ratings obtained were compared to
those taken before the treatment. Statistical analyses were
performed using the mean, standard deviation, median, or
relative and absolute frequencies. The scores were normally
distributed (Kolmogorov-Smirnov test). The paired t-test
was used to compare the scores and values before and after
the treatment. We assumed p= 0.05 to be significant and
used SAS 9.2 software (SAS Institute, Cary, NC, USA) to
analyze the results. All of the patients had their TSH, free
T4, hemoglobin and ferritin levels determined at the
beginning of the trial.
& RESULTS
The age of the patients ranged from 12 to 76 years
(median 48 years), and their median WED severity score,
according to the International Restless Legs Syndrome
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Study Group (IRLSSG) (39-41), ranged from 17 to 36
(median 24). After the initial ten-day treatment, 17 patients
(81%) (14 female) reported experiencing .70% improve-
ment of their WED symptoms and also reported better sleep
during the treatment compared to before the treatment
(Table 2).
Regarding compliance with the first treatment phase, 11
patients reported that they did not take SJW for one day
during the ten day-trial, and four patients did not take SJW
on two days of the trial. The age of this successful ten-day
treatment group was between 12 and 76 years, with an
average of 49.2¡17.7 years and a median age of 53 years.
Four patients (two female) reported no improvement
during the ten-day trial, all of whom were drug-naı¨ve (ages
21, 42, 45 and 56 years, median WED severity score of 24).
Of these four patients, two decided to take pramipexole,
after which their WED symptoms were alleviated entirely.
Two patients did not return for another interview. All of the
patients whose symptoms were alleviated by the ten-day
SJW trial agreed to take the drug for three more additional
months. All of the patients in this second phase of the trial
did not take the drug daily. The patients reported that
during the three-month second-phase trial, they took the
drug on average for 40 days. They stopped taking the drug
for a few days, and then when the WED symptoms
returned, they resumed taking the drug for a few days (3-
5 days), and so on. Following cessation of the drug, the
patients reported that they remained free of WED symp-
toms for 2-7 days (median 3). After completing the three-
month trial, all 17 patients reported a desire to continuously
take SJW as a WED treatment. At the beginning of the trial,
these 17 patients scored a median of 24 (¡5.1) points in the
IRLSSG rating severity scale, and after the three-month
treatment, the score was 4.1 (¡1). When the paired t-test
was applied to compare scores and values before and after
treatment, p,0.0001 was obtained (Figure 1).
The TSH and free T4 levels measured in all of the patients
showed results in the normal reference range for these
parameters. None of the patients was anemic, and eight had
ferritin levels under 45 mg/L (after the end of the trial they
received iron therapy). In this open-label trial, SJW did not
cause any side effects in any of the patients.
& DISCUSSION
The results of this pilot trial suggest that SJW may be an
effective treatment for some WED patients. However, as this
trial was not placebo-controlled, the extent to which SJW is
effective as a WED treatment will depend on future,
blinded, placebo-controlled studies, which could minimize
the placebo effect. We do not advocate that SJW should be
considered as a definitive treatment for WED; however, we
believe that SJW alleviated WED symptoms of the patients
studied because it decreased TH levels by increasing TH
degradation through the CYP3A4 enzyme isoform and,
perhaps, by increasing Pgp expression. The results of this
trial, despite its limitations, seem to add evidence favoring
the IMBTH/DA theory as being central to WED pathophy-
siology. Interfering with the expression of CYP3A4, and
perhaps also with Pgp, may decrease the severity of WED
symptoms.
Four patients did not experience relief from their WED
symptoms, most likely because the extent to which the SJW
enhanced their CYP3A4 TH metabolism was not sufficiently
high (or the SJW dose used was too small) to decrease TH to
lower levels that are compatible with DA counteraction. As
explained in the introductory part of this manuscript, there
are four pharmacological goals for WED drugs: 1) dimin-
ishing the TSH release, 2) enhancing the CYP3A4 expres-
sion, 3) modulating the WED sensation inputs on their
pathway from the peripheral sensory receptors to the
sensory cortex, and 4) diminishing the TH release by the
thyroid gland by decreasing the SS activity. SJW most likely
relieved the symptoms of the WED patients studied only by
enhancing the expression of the CYP3A4 isoform. It is also
theoretically possible that SJW alleviated WED symptoms
by increasing the activity of the dopaminergic system.
However, this specific action of SJW is recognized as mild
and therefore most likely did not affect this trial. The
IMBTH/DA of the WED patients is most likely subtle. In
most WED cases, hyperthyroidism is not more prevalent
than it is in normal subjects; therefore, the normal TSH and
TH levels observed in all of the patients were not
unexpected. During the second phase of the trial, all of the
patients were able to become free of WED symptoms for a
few days during brief interruptions of the SJW treatment. It
is common that the induction or inhibition of CYP450 by
xenobiotics lasts for a variable time after exposure to the
drug is stopped. Thus, the few days of relief from WED
symptoms after the SJW treatment was stopped were not
unexpected.
Final considerations
A better understanding of the mechanisms by which
drugs ameliorate or worsen WED symptoms may help in
the development of new strategies for WED treatment.
Furthermore, WED can be considered to be a condition
Table 2 - Results for 21 WED patients treated with SJW.
The alleviation of WED symptoms (percentage of relief)
after the first ten-day treatment and subjective
impressions of sleep quality improvement.
Patients % of Relief Batter Sleep
14 100% Yes
2 80% Yes
1 70% Yes
1 20% No
3 0% No
Figure 1 - Average (with standard deviation) WED severity scores
pre- and post-treatment for the 17 successful patients. Paired t-
test: p,0.0001
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whose severity may be influenced by interactions between
xenobiotics and endogenous compounds. For WED patients,
the importance of the CYP4503A4 isoform is magnified, and
some practical issues may arise. For instance, it may not be
advisable for these patients to consume grapefruit juice
(popular in the United States) because it is a strong inhibitor
of the CYP4503A4 isoform that may thus increase the
severity of WED symptoms. Caffeine is also a moderate
inhibitor of CYP4503A4; thus, the recommendation of
refraining from caffeine after 4 PM might not be sufficient
for WED patients because it is possible that the resulting
CYP3A4 inhibition will persist well beyond the average
half-life of caffeine. As Pgp is able to decrease the TH
content of cells, it is reasonable to infer that this protein may
also be involved in the fine adjustment of TH physiology.
For the treatment of any health problem other than WED,
therefore, it would be best for a WED patient to choose a
treatment that does not inhibit CYP4503A.
In spite of the inherent limitations of this open-label trial,
we hope that its rationale and results may encourage further
studies, including larger blind placebo-controlled trials that
could demonstrate the extent to which SJW could be used to
treat WED.
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